This report presents our experience with T therapy in a cohort of T-deficient men on active surveillance (AS) for Gleason 3 + 3 and Gleason 3 + 4 prostate cancer (PCa). A retrospective chart review identified 28 men with T deficiency who underwent T therapy (T group) for at least 6 months while on AS for PCa.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
A comparison group of 96 men on AS for PCa with untreated T deficiency (no-T group) was identified at the same institution. The AS protocol followed a modified Epstein criteria and allowed inclusion of men with a single core of low-volume Gleason 3 + 4 PCa. Mean age was 59 5 and 61 3 years, and mean follow-up was 38 9 and 42 4 months for the T and no-T groups, respectively. Of all 28 men in the T group, 3 (10 7%) men developed an increase in Gleason score while on AS. Of 22 men in the T group with Gleason 3 + 3 disease, 7 (31 8%) men developed biopsy progression including 3 men (13 6%) who developed Gleason 3 + 4 PCa Of 6 men with Gleason 3 + 4 disease at baseline, 2 (33 3%) men developed an increase in tumor volume, and none developed upgrading beyond Gleason 3 + 4 All 96 men in the no-T group had Gleason 3 + 3 disease at baseline and, 43 (44 7%) developed biopsy progression, including 9 men (9 38%) with upgrading to Gleason 7 (3 + 4). Biopsy progression rates were similar for both groups and historical controls. Biopsy progression in men on AS appears unaffected by T therapy over 3 years. Prospective placebo-controlled trials of T therapy in T-deficient men on AS should be considered given the symptomatic benefits experienced by treated men.
Asian journal of andrology 2015 Aug 21 [Epub ahead of print]
Ravi Kacker, Hult Mariam, Ignacio F San Francisco, William P Conners, Pablo A Rojas, William C Dewolf, Morgentaler Abraham
Men's Health Boston, Brookline, MA, USA